BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8067710)

  • 1. Pharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine(glycolato)platinum, 254-S.
    Ota K; Oguma T; Shimamura K
    Anticancer Res; 1994; 14(3B):1383-7. PubMed ID: 8067710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics of cis-diammine (glycolato) platinum (254-S), a new platinum antitumor agent, following an intravenous and intraperitoneal infusion bioactive platinum concentration profile].
    Hirabayashi K; Okada E; Oguma T; Shimamura K
    Gan To Kagaku Ryoho; 1990 Nov; 17(11):2221-7. PubMed ID: 2241186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
    Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of platinum following the administration of cis-(glycolato-O,O')[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3-dioxolane]platinum(II) in dogs.
    Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
    Anticancer Res; 1997; 17(5A):3681-3. PubMed ID: 9413223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
    Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.
    Baur M; Drescher A; Gneist M; Dittrich C; Jaehde U
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):97-104. PubMed ID: 17396265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II)].
    Ota K; Wakui A; Majima H; Niitani H; Inuyama Y; Ogawa M; Ariyoshi Y; Yoshida O; Taguchi T; Kimura I
    Gan To Kagaku Ryoho; 1992 Jun; 19(6):855-61. PubMed ID: 1605663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.
    Gamelin E; Bouil AL; Boisdron-Celle M; Turcant A; Delva R; Cailleux A; Krikorian A; Brienza S; Cvitkovic E; Robert J; Larra F; Allain P
    Clin Cancer Res; 1997 Jun; 3(6):891-9. PubMed ID: 9815764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetics of carboplatin (CBDCA) and tissue concentration of platinum in gynecologic organs].
    Fujiwara K; Miyagi Y; Hayase R; Yoshinouchi M; Kobashi Y; Kohno I; Sekiba K
    Gan To Kagaku Ryoho; 1988 Jun; 15(6):1943-8. PubMed ID: 3289504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
    Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
    Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of a new platinum compound, cis-(glycolato-O,O) [(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclohexane]plat inum (II) in dogs.
    Kim DK; Cho YB; Kim HT; Kim TS; Kim KH; Hong WS
    Anticancer Res; 1996; 16(3A):1167-9. PubMed ID: 8702230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
    Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
    Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin.
    Sasaki Y; Tamura T; Eguchi K; Shinkai T; Fujiwara Y; Fukuda M; Ohe Y; Bungo M; Horichi N; Niimi S
    Cancer Chemother Pharmacol; 1989; 23(4):243-6. PubMed ID: 2647312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients.
    Urien S; Brain E; Bugat R; Pivot X; Lochon I; Van ML; Vauzelle F; Lokiec F
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):55-60. PubMed ID: 15258698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
    Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
    Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
    Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
    Harland SJ; Newell DR; Siddik ZH; Chadwick R; Calvert AH; Harrap KR
    Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of oxaliplatin: a critical review.
    Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
    Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.